Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by Stable Gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine
BPC-157 is classified as a Category 2 bulk drug substance as of April 2026, meaning it is prohibited in compounding under Section 503A and 503B
Clinical Trial Safety Data: Across multiple studies using oral and intravenous AOD-9604 for up to 24 weeks, the peptide demonstrated an excellent safety profile indistinguishable from placebo
Possible Side Effects of Semaglutide and AOD9604 Use Semaglutides safety profile is excellent in fact, it already has a great head start as a non-stimulant appetite suppressant
By December, Enterobacteriaceae dropped to 0.236%
Studies suggest that BPC-157 interacts with multiple biological pathways simultaneously, which distinguishes it from many single-target peptides